itheranostics

At Theragnostics, we explore, invest in, and develop promising early stage intellectual property in the field of nuclear medicine. Our decision-making is driven by a highly skilled executive team and an unparalleled Medical Advisory Panel of exceptional clinicians who share the same vision of integrating theragnostics into the clinic to enhance understanding and combat disease. We endorse a cooperative model, collaborating with the academic, scientific, and clinical community to establish enduring value. Our objective is to structure licensing agreements for novel technology that has the potential to revolutionize patient diagnosis and treatment in the clinic. Theragnostics was established in the United Kingdom in 2015 with the goal of offering a range of products to revolutionize patient care in oncology through targeted molecular radiotherapy and molecular imaging diagnostic products. The term Theragnostics is derived from Therapy and Diagnostics, and embodies the strategy of using radioactively labeled drugs, enabling us to capture images of disease with a radioactive isotope for diagnostic and treatment planning purposes. Subsequently, the same disease can be treated by transitioning to a therapeutic radioactive isotope.